PLYMOUTH, Mich.--(BUSINESS WIRE)--Today, Materialise (NASDAQ:MTLS) and Tissue Regeneration Systems (TRS) announce a partnership to manufacture life-saving 3D-Printed tracheal splints for use in clinical trials.
Materialise’s Mimics Innovation Suite was used to design the splint which is constructed from a bioresorbable technology platform licensed to TRS by the University of Michigan in 2007. After several years refining fabrication methods, TRS received its first commercial product clearance from the FDA in 2013. The Materialise partnership is one of several co-development projects currently underway at TRS.
Thanks to FDA approval for Expanded Access to an investigational medical device, the splints are used to treat tracheobronchomalacia (TBM), a condition affecting 1 in 2,220 babies which can cause the airway to spontaneously collapse.
“The collaboration between TRS and Materialise will provide production capacity for the tracheal splint, which will allow the splint to be available to a larger number of infants who are affected with TBM,” stated Bryan Crutchfield, Managing Director, Materialise USA.
“We are excited to have the opportunity to impact the lives of children affected with TBM through the production of the tracheal splint,” says Jim Fitzsimmons, CEO of TRS.
About Materialise
With its headquarters in Leuven, Belgium,
and branches worldwide, Materialise is a provider of Additive
Manufacturing (AM) software solutions and sophisticated 3D printing
services in a wide variety of industries, including healthcare,
automotive, aerospace, art and design and consumer products. Materialise
has been playing an active role in the field of AM since 1990, through
its involvement in AM for industrial and medical applications, by
providing biomedical and clinical solutions such as medical image
processing and surgical simulations and by developing unique solutions
for its customers' prototyping, production, and medical needs. For
additional information, please visit: www.materialise.com.
About Tissue Regeneration Systems
Founded in 2007 with
principal operations in Plymouth, Michigan, Tissue Regeneration Systems
is an early-stage medical device company commercializing a breakthrough
skeletal reconstruction and bone regeneration technology platform
developed from ground breaking research conducted at the Universities of
Michigan and Wisconsin. To learn more about TRS, visit the company's
website at www.tissuesys.com
Cautionary Statement on Forward-Looking Statements
This
press release contains forward-looking statements regarding, among other
things, the plans, objectives, expectations, strategies and prospects of
the Company, both financial and business. Such statements are subject to
known and unknown uncertainties and risks. When used in this press
release, the words “estimate,” “expect,” “anticipate,” “project,”
“plan,” “intend,” “believe,” “forecast,” “will”, “may”, “could”,
“might”, “aim”, “should” and variations of such words or similar
expressions are intended to identify forward-looking statements. These
forward-looking statements are based upon the management’s current
expectations. These expectations, beliefs and projections are given in
good faith and management believes there is a reasonable basis for them.
However, the management cannot offer any assurance that its
expectations, beliefs and projections will actually be achieved. By
their nature, forward-looking statements involve risks and uncertainties
because they relate to events, competitive dynamics and industry change,
and depend on economic circumstances that may or may not occur in the
future or may occur on longer or shorter timelines than anticipated.
Management cautions readers that forward-looking statements are not
guarantees of future performance and involve known and unknown risks,
uncertainties and other factors that are in some cases beyond its
control. All of the forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from
expectations. Management makes no commitment, and disclaims any duty to
update or revise any forward-looking statements to reflect future events
or changes in its expectations.
